SAN DIEGO, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Receptos Inc. (Nasdaq:RCPT) today announced that Company personnel will deliver two scientific poster presentations about RPC1063 at the annual meeting of the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark during October 2-5, 2013. RPC1063 is the Company's lead sphingosine 1-phosphate 1 receptor (S1P1R) modulator in Phase 2 development for both relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD).
The first Receptos poster presentation is titled "Results of a thorough QT/QTc (TQT) study of orally administered RPC1063, a novel, selective S1P1 receptor (S1P1R) agonist, in healthy adult volunteers." The data presented in the poster demonstrate that at steady state, therapeutic and supratherapeutic doses of RPC1063 had no adverse effect on cardiac repolarization as measured by the effects on Fridericia corrected QT interval (QTcF), ruling out a relevant effect of RPC1063 on QT interval. The dose titration regimen employed during the study appeared to attenuate first dose heart rate effects and was well tolerated throughout the titration period. No notable safety issues were identified.
The second Receptos poster presentation is titled "RPC1063, a potent and selective S1P1R modulator, has a favorable preclinical safety profile." The data presented in the poster demonstrate an encouraging preclinical safety profile for RPC1063, in which RPC1063 was well tolerated in animal toxicology studies up to 9 months in duration, with a wide margin of safety relative to estimated human therapeutic exposures. In addition, the absence of fibrotic changes is consistent with the selectivity of RPC1063 towards the S1P1R.
"We continue to build upon our clinical and preclinical experience with RPC1063 in RMS," said Faheem Hasnain, President and Chief Executive Officer of Receptos. "In particular, the lack of effect of RPC1063 on QT prolongation and the modest impact on heart rate appears to demonstrate a favorable cardiac safety profile."
Thursday, October 03 at 15:45 Poster Session 1 - Experimental models Poster 375:
"RPC1063, a potent and selective sphingosine 1-phosphate 1 receptor modulator, has a favourable preclinical safety profile"
Friday, October 04 at 15:30 Poster Session 2 - Immunomodulation/Immunosuppression Poster 983:
"Results of a thorough QT/QTc (TQT) study of orally administered RPC1063, a novel, selective S1P1 receptor agonist, in healthy adult volunteers"
About RPC1063 and S1P1R Modulators
RPC1063 is a novel, oral, once daily, selective and potent S1P1R modulator in development for autoimmune indications. Previously reported Phase 1 results demonstrated adequate pharmacokinetic, pharmacodynamic and safety features, which provide supportive data for the differentiation strategy for RPC1063 as a potential best-in-class second generation S1P1R modulator. Receptos is on track for enrollment completion in Q4 2013 in the randomized Phase 2 portion of a Phase 2/3 study called RADIANCE examining the efficacy, safety and tolerability of RPC1063 in RMS and is enrolling a randomized Phase 2 study called TOUCHSTONE examining the efficacy, safety and tolerability of RPC1063 in ulcerative colitis (UC). Top-line results for both studies are expected in mid-2014.
About Receptos
Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company's lead program, RPC1063, is an S1P1R small molecule modulator candidate for immune indications, including RMS and IBD. The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated Orphan Disease, eosinophilic esophagitis (EoE). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs).
Forward-Looking Statements
Statements contained in this release, other than statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "expects," "believes," "may," "intends," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that forward-looking statements, including without limitation statements regarding the safety, efficacy and projected development timeline of drug candidates such as RPC1063 as well as statements regarding the scope and strength of intellectual property protection, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include without limitation risks associated with the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. These and other risks are described in detail in the Company's SEC filings, including the Company's Quarterly Reports on Form 10-Q and the Company's Registration Statement on Form S-1 which was declared effective on May 8, 2013. All forward-looking statements contained in this release speak only as of the date on which they were first made by the Company, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after such date.